AVTX
Avalo Therapeutics Inc

13,731
Loading...
Loading...
News
all
press releases
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry...
PR Newswire·11mo ago
News Placeholder
More News
News Placeholder
The Lustgarten Foundation Appoints Two New Board Members
The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...
PR Newswire·1y ago
News Placeholder
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction...
Benzinga·1y ago
News Placeholder
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...
Globe Newswire·1y ago
News Placeholder
Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?
Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of...
Invezz News·1y ago
News Placeholder
Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M
Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M...
SeekingAlpha.com: All News·1y ago
News Placeholder
Avalo Reports 2023 Financial Results and Provides Business Updates
Acquired AVTX-009, Phase-2 ready anti-IL-1 mAb, in March 2024Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment...
Globe Newswire·1y ago
News Placeholder
12 titres de soins de sant en mouvement lors de la session du 29/03/2024
Gagnants L'action Avalo Therapeutics (NASDAQ:AVTX) a augment vendredi de 364,84% 22,08 dollars lors de la session ordinaire. Le titre Nexalin Technology (NASDAQ:NXL) a augment de 83,33% 1,43...
Benzinga·1y ago
News Placeholder
12 titres de soins de sant en mouvement lors de la pr -ouverture le 29/03/2024
Gagnants Le titre Avalo Therapeutics (NASDAQ:AVTX) a mont vendredi de 289,05% 18,48 dollars lors de la session pre-market. Le titre Xilio Therapeutics (NASDAQ:XLO) a grimp de 205,16% 1,95...
Benzinga·1y ago
News Placeholder
12 titoli sanitari in movimento, pre-market del 29/03/2024
Titoli in rialzo Le azioni di Avalo Therapeutics (NASDAQ:AVTX) sono cresciute del 289,05% a 18,48 dollari durante la sessione pre-market di venerd . Il titolo Xilio Therapeutics (NASDAQ:XLO) salito...
Benzinga·1y ago

Latest AVTX News

View

Advertisement. Remove ads.

Advertisement. Remove ads.